10649 studies found for:    NCI
Show Display Options
Rank Status Study
21 Not yet recruiting Berberine Chloride in Treating Patients With Ulcerative Colitis in Remission
Condition: Ulcerative Colitis
Interventions: Drug: Berberine Chloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
22 Not yet recruiting Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
Conditions: Recurrent Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Drug: Glembatumumab Vedotin;   Other: Laboratory Biomarker Analysis
23 Recruiting Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas or Diffuse Intrinsic Pontine Gliomas
Conditions: Diffuse Intrinsic Pontine Glioma;   Malignant Glioma;   Recurrent Childhood Brain Neoplasm
Interventions: Procedure: Diffusion Tensor Imaging;   Procedure: Diffusion Weighted Imaging;   Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging;   Procedure: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging;   Other: Laboratory Biomarker Analysis;   Procedure: Magnetic Resonance Spectroscopic Imaging;   Biological: Pembrolizumab;   Procedure: Perfusion Magnetic Resonance Imaging
24 Not yet recruiting Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers
Conditions: Lung Carcinoma;   Tobacco Use Disorder
Interventions: Drug: Aspirin;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Drug: Zileuton
25 Not yet recruiting Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
Conditions: Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Tumor;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Other: Pharmacological Study
26 Not yet recruiting Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma of the Skin;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Biological: Sargramostim
27 Not yet recruiting Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer
Conditions: Nasopharyngeal Nonkeratinizing Carcinoma;   Recurrent Nasopharyngeal Undifferentiated Carcinoma;   Stage III Nasopharyngeal Undifferentiated Carcinoma;   Stage IV Nasopharyngeal Undifferentiated Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
28 Not yet recruiting Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-versus-Host Disease
Condition: Progressive cGVHD
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Vismodegib
29 Recruiting Rilimogene-Galvacirepvec in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance
Conditions: Prostate Adenocarcinoma;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Other: Placebo;   Biological: Rilimogene-galvacirepvec
30 Not yet recruiting Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors
Condition: Malignant Digestive System Neoplasm
Interventions: Drug: Alisertib;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin
31 Not yet recruiting PARP Inhibitor BMN-673, Carboplatin, and Paclitaxel in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Condition: Adult Solid Neoplasm
Interventions: Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study;   Drug: Talazoparib
32 Recruiting Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis
33 Recruiting Nivolumab in Treating Patients With Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
Conditions: Anal Canal Squamous Cell Carcinoma;   Metastatic Anal Canal Carcinoma;   Recurrent Anal Canal Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
34 Recruiting Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Recurrent Breast Carcinoma;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Tamoxifen Citrate;   Drug: Z-Endoxifen Hydrochloride
35 Suspended Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Conditions: Glioblastoma;   Gliosarcoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Temozolomide
36 Completed Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Conditions: Chemotherapeutic Agent Toxicity;   Neuropathy;   Neurotoxicity Syndrome;   Pain;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: Carboplatin;   Drug: Glutathione;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Placebo;   Other: Quality-of-Life Assessment
37 Recruiting Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Conditions: Metastatic Ewing Sarcoma;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Bone Marrow;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone;   Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Radiation: External Beam Radiation Therapy;   Biological: Ganitumab;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Radiation: Stereotactic Radiosurgery;   Procedure: Therapeutic Surgical Procedure;   Drug: Vincristine Sulfate
38 Recruiting Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Conditions: Childhood Solid Neoplasm;   Recurrent Childhood Hodgkin Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Pharmacological Study
39 Recruiting Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors
Conditions: Adult Solid Neoplasm;   Metastatic Melanoma;   Metastatic Renal Cell Cancer;   Recurrent Colorectal Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage IV Ovarian Cancer;   Stage IVA Colorectal Cancer;   Stage IVB Colorectal Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Biological: Ziv-Aflibercept
40 Recruiting Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy
Condition: Adult Acute Myeloid Leukemia in Remission
Interventions: Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years